Findings from the phase 3 KEYNOTE-564 trial support adjuvant pembrolizumab following nephrectomy as a standard-of-care treatment for patients with clear cell renal cell carcinoma.
Kidney Cancer Research Summit (KCRS)
The improvements occur regardless of PD-L1 status among patients receiving lenvatinib plus pembrolizumab for advanced renal cell carcinoma in the phase 3 CLEAR study.
Advertisement
Using a laser ablation system, imaging mass cytometry is designed to measure over 40 metal isotopes in a tumor sample to identify how immune cells in clear cell renal cell carcinoma are organized.
Advertisement
Advertisement
Trending on CancerNetwork
1
New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer
2
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
3
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
4
CEA-High Expression Shows Early Promise as a Biomarker for BG-C477 in NSCLC
5